Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced that the Temple University team collaborating with Excision on a project, CRISPR for Cure, has received a Martin Delaney Grant from the National Institutes of Health (NIH) of $4.8 million on an annual basis for the next five years as a part of approximately $53 million
annual funding from the NIH to find a cure for HIV. Research will be done at Temple University, as well as the University of California, Los Angeles, Washington University School of Medicine, St. Louis, Case Western Reserve University, Drexel University College of Medicine, and the Scripps Research Institute. The funding has been awarded to 10 research organizations as a part of the expansion of the Martin Delaney Collaboratories program to expedite HIV cure research by bringing together researchers from multiple academic institutions, the private sector, and government partners. The announced investment is an expansion from the original 2016 program from 6 research collaborations and $30 million in annual funding.
“The NIH Martin Delaney Grant, of which the investigation of CRISPR-based curative therapies is a part, demonstrates the commitment of the NIH to find a cure for an infectious disease for which no vaccines are available and treatments only manage the disease,” said Daniel Dornbusch, Chief Executive Officer of Excision. “It is a privilege to collaborate with Dr. Kamel Khalili of Temple University to further develop our CRISPR-based HIV DNA ablation therapeutic, EBT-101, and we look forward to advancing the program towards clinical trials.”
Read the full article here.